A Phase II, Open Label, Randomized, Multicenter Trial Comparing Noncontrast MRA Versus Ferumoxytol Vascular Enhanced MRI (VE-MRI) for the Detection of Clinically Significant Stenosis or Occlusion of the Aortoiliac and Superficial Femoral Arteries in Subjects With Peripheral Arterial Disease Scheduled for Digital Subtraction Angiography (DSA)
Latest Information Update: 05 Apr 2021
At a glance
- Drugs Ferumoxytol (Primary)
- Indications Peripheral arterial disorders
- Focus Diagnostic use
- Sponsors AMAG Pharmaceuticals
Most Recent Events
- 25 Apr 2019 Planned End Date changed from 1 Dec 2016 to 1 Aug 2019.
- 19 Sep 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016.
- 15 Sep 2014 New trial record